Melanoma in Practice: Nurse Conference
26 July 2018
It was a full house this week at Melanoma Institute Australia thanks to our ‘Melanoma in Practice: Nurse Conference’. Designed specifically for nurses, the presentations were designed to give nurses a better understanding of the patient experience from detection through to treatment of advanced disease and included updates in the latest areas of research that are changing the way we treat melanoma.
Presentations were given by melanoma specialists in dermatology, pathology, medical oncology, surgery, radiotherapy, physiotherapy, psychology and clinical trials, as well as melanoma survivors and CNCs who are directly involved in melanoma care
Highlights included a presentation from Associate Professor Robyn Saw who discussed the processes of surgical management of melanoma Stages 0-IV and how “understanding the anatomy is essential for diagnosing and treating melanoma”.
A key takeaway from the conference was a presentation by Associate Professor Matteo Carlino. Associate Professor Carlino delved into the system therapy for the treatment of advanced melanoma and notably pointed out how there has been a shift in nurses’ role in melanoma. “It used to be that advanced melanoma nurses worked primarily on palliative care. We're now in a time where nurses are working on survivorship care”, said Associate Professor Carlino, a statement that really resonated with the audience.
We’d like to thank those who attended and engaged with the conference. One attendee said that ‘all the sessions were so informative and the presenters had a real passion for their work’ and we hope that all attendees found it both enjoyable and beneficial.
The presentations from the Nurse Conference will be made available on our free melanoma education portal for healthcare practitioners in the next few weeks. If you’re a nurse, we encourage you to register your interest at www.melanomaeducation.org.au to be the first to know when they become available.
The Federal Government’s 2015-16 Budget was announced this week with a boost for medical research funding.
The Association's members include prominent surgeons from around the world.
MIA leads the world-first study that finds anti–PD-1 antibody pembrolizumab increases the survival of patients
This is a landmark study, the first in a class of drugs that will change the future of treatment for all cancers.
Australia is the first country in the world to register anti-PD1 for the first line treatment of unresectable or metastatic melanoma in adults.
We have a winner!
Professor John Thompson, Executive Director at Melanoma Institute Australia, was one of 116 fellows appointed to the new Australian Academy of Health and Medical Sciences at a ceremony in Canberra on the 25th March.
Federal Minister for Health, the Hon. Sussan Ley, announced more than $14 million in funding for a research program to study the molecular determinants of risk, progression and treatment response in melanoma.
If you would like to download a bib for your Melanoma March, we have a selection for you to choose from, print and bring along with you on the day.
Manly Melanoma March has changed to a new location.
We did a short Q&A with two sisters who are raising funds for Melanoma March after sadly losing their mother in 2009. This is their second march and they have shared with us their fundraising tips.
We want to share with you what your valuable Melanoma March donation and fundraising goes towards and our Research Director, Graham Mann explains the national research project the funds will be going towards.
Evaluation of Groin Lymphadenectomy Extent for Metastatic Melanoma (EAGLE FM) clinical trial has recruited its first patient.
You are invited to provide comments for consideration by the Pharmaceutical Benefits Advisory Committee (PBAC). The PBAC will consider the registration of the anti-PD1 drug, Keytruda (pembrolizumab) at the next meeting in March.
Melanoma patient Joel Allsop was congratulated today on completing his participation in the international surgical clinical trial, known as MSLT-II. He was the first person in the world to complete the 10 years of follow-up for this trial.
Melanoma Institute Australia (MIA) has officially launched the 2015 ‘Melanoma March’ initiative in Melbourne.
Help us march towards a cure for melanoma research. See where your local march is and how you can get involved.
Under the leadership of world-leading melanoma pathologist Prof Richard Scolyer and medical oncologist A/Prof Georgina Long, third year PhD student, Hojabr Kakavand, is at the forefront of melanoma research.
Melanoma Institute Australia has launched a new smartphone app called ClinTrial Refer Melanoma to help busy clinicians find clinical trials for their melanoma patients.
MIA's Associate Professor Georgina Long and stage 4 melanoma patient, Maria, were recently interviewed by ABC Weekend Breakfast about the latest in clincial trials and melanoma treatments.